Chemoprevention with the cyclooxygenase 2 (COX-2) inhibitor celecoxib (5) and with a combination of the nonselective COX inhibitor sulindac and the epidermal growth factor receptor (EGFR) inhibitor erlotinib (6) have shown promise in decreasing polyp burden although long-term effect on cancer risk is unknown. This evidence concerns the gene PTGS2 and cancer.